Repository of Research and Investigative Information

Repository of Research and Investigative Information

Baqiyatallah University of Medical Sciences

A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide

(2020) A time to revisit the two oldest prandial anti-diabetes agents: acarbose and repaglinide. Endocrine. pp. 307-313. ISSN 1355-008X

[img] Text
A time to revisit the two oldest prandial anti-diabetes agents acarbose and repaglinide.pdf

Download (465kB)

Official URL:


Purpose Compared with newer prandial anti-diabetes agents, repaglinide and acarbose are unique in being globally available in generic versions, being oral, and being the cheapest of all. The aim of this study was to compare their efficacy when used alone or in combination. Methods In a randomized, double-blind, prospective study, 358 recently diagnosed type 2 diabetes (T2D) patients, who on a combined therapy with metformin and insulin glargine had a fasting plasma glucose (FGP) of <7.2 mmol/L but a 2-h postprandial plasma glucose (2hPPG) >10 mmol/L, were assigned to three groups of additional treatment with either repaglinide, acarbose, or repaglinide-plus-acarbose for 4 months. Results With intention-to-treat analysis, 63 of repaglinide group, 45.4 percent of acarbose group, and 75.7 of repaglinide-plus-acarbose group reached the primary endpoint of 2hPPG < 10 mmol/L while maintaining FPG < 7.2 mmol/L. Treatment adherence rate was 75.6 with repaglinide, 61.4 with acarbose, and 81.3 with repaglinide-plus-acarbose (p = 0.001). Among the groups, weight was significantly lower in acarbose group (p < 0.05). Twenty-one percent of repaglinide patients, 4.9 of acarbose subjects, and 10.3 of repaglinide-plus-acarbose cases reported at least one episode of hypoglycemia (p < 0.005). HbA1C and basal insulin requirement were significantly lower in repaglinide group (p = 0.004,p = 0.0002). Triglycerides were lowest in acarbose group (p = 0.005). Conclusions Both acarbose and repaglinide were vastly effective in lowering postprandial hyperglycemia of recently diagnosed T2D. When combined, they were even more efficacious and the disease had a better outcome. Compared with newer peers, these two are particularly useful where and when cost consideration in diabetes treatment is a prime concern.

Item Type: Article
Keywords: Type 2 diabetes (T2D) Postprandial hyperglycemia Acarbose Repaglinide Treatment adherence type-2 adherence therapy drugs Endocrinology & Metabolism
Page Range: pp. 307-313
Journal or Publication Title: Endocrine
Journal Index: ISI
Volume: 70
Number: 2
Identification Number:
ISSN: 1355-008X
Depositing User: مهندس مهدی شریفی

Actions (login required)

View Item View Item